HistoSonics, (www.histosonics.com), the developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the first kidney patient has been treated using the Company’s histotripsy platform. The procedure was performed in Leeds, UK, by Professor Tze Min Wah, Senior …
Trending at Lumira Ventures
HistoSonics Announces $100 Million in Financings and New Appointment to its Board of Directors
Financings Planned to Support Rapid Expansion of Histotripsy Platform as Company Welcomes Silk Road Medical CEO, Erica Rogers, to its Board of Directors HistoSonics, Inc. (www.histosonics.com), the developer of a non-invasive, novel sonic beam therapy, announced today that it has raised $85 …
HistoSonics Hits Pivotal Clinical Trial Milestone In #HOPE4LIVER Studies
Company Continues to Build as It Prepares for FDA Submission and Clearance of Its Breakthrough Therapy HistoSonics, the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the fulfillment of patient enrollment required for …
HistoSonics Announces Agreement with GE Healthcare
MINNEAPOLIS, May 23, 2022 — HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agreement formalizing ongoing efforts to use GE Healthcare’s LOGIQ E10 Series ultrasound imaging platform to power the real time visualization features of …
HistoSonics Receives FDA “Breakthrough Device Designation” for Novel Sonic Beam Therapy
HistoSonics, the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its new therapy platform. Histotripsy of …
American Medical Association (AMA) issued the first ever, unique CPT code for histotripsy of the liver
HistoSonics, the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, today announced that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) code for histotripsy of the liver. Histotripsy of …
HistoSonics Appoints Dr. Joe Amaral to Position of Vice President of Medical Affairs.
MINNEAPOLIS, Sept. 9, 2020 /PRNewswire/ — HistoSonics, developer of the non-invasive Edison platform and novel sonic beam therapy, announced today the appointment of Joe Amaral, MD, to the newly created position of Vice President of Medical Affairs, where he will oversee global clinical development …
HistoSonics Announces $40 Million Financing
Breakthrough medical platform offers vision of non-invasive procedures to eliminate diseased tissues and tumors MINNEAPOLIS, June 8, 2020 /PRNewswire/ — HistoSonics, developer of a non-invasive robotic platform and sonic beam therapy, announced today that it has closed $40 million in an …
Histotripsy Tumor Ablation Research is Published in the Journal for ImmunoTherapy of Cancer
On January 15, 2020, HistoSonics’ research on non-thermal histotripsy tumor ablation was published in the Journal for ImmunoTherapy of Cancer (JITC), the premier cancer immunotherapy journal at BMC and the official journal of the Society for Immunotherapy of Cancer (SITC). …
HistoSonics Leads The Observer’s 2020 List of Innovative Healthcare Companies
PLYMOUTH, Minn. /PRNewswire/ — HistoSonics, developer of a novel non-invasive sonic beam therapy platform, was named by The Observer as one of the nation’s most influential healthcare companies during the 38th J.P. Morgan Healthcare Investment Conference in San Francisco, CA. The …
HistoSonics Receives 2019 Frost & Sullivan Technology Innovation Award
SAN ANTONIO /PRNewswire/ — Frost & Sullivan, a leading global research and analysis firm, announced that it has awarded HistoSonics its prestigious 2019 North American Technology Innovation Award for the development of the company’s new breakthrough platform, designed to destroy solid …
HistoSonics Touts First-in-Human Study Results
HistoSonics announced its non-invasive robotics platform and novel sonic beam cancer therapy successfully destroyed 11 tumors in eight patients during its first clinical trial. The results were presented this week at the 2019 Society of Interventional Oncology (SIO) Annual Meeting …
HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing
Breakthrough medical platform offers vision of personalized tumor treatments with its novel sonic beam therapy ANN ARBOR, MICHIGAN // Apr. 8, 2019 – HistoSonics, developer of a non-invasive robotics platform and novel beam therapy, announced today that it has closed …